LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.00 million shares of its common stock in an underwritten public offering. In connection with this offering, Synageva expects to grant to the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock. If the underwriters exercise this option, Synageva will have offered 2.30 million shares of its common stock. Goldman, Sachs & Co., J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are serving as book-running managers for the offering.
Help employers find you! Check out all the jobs and post your resume.
